0.67
+0.0147(+2.24%)
Currency In USD
| Previous Close | 0.66 |
| Open | 0.67 |
| Day High | 0.69 |
| Day Low | 0.65 |
| 52-Week High | 1.93 |
| 52-Week Low | 0.5 |
| Volume | 57,854 |
| Average Volume | 513,822 |
| Market Cap | 29.45M |
| PE | -0.43 |
| EPS | -1.55 |
| Moving Average 50 Days | 0.99 |
| Moving Average 200 Days | 0.97 |
| Change | 0.01 |
If you invested $1000 in Xilio Therapeutics, Inc. (XLO) since IPO date, it would be worth $41.88 as of February 05, 2025 at a share price of $0.67. Whereas If you bought $1000 worth of Xilio Therapeutics, Inc. (XLO) shares 3 years ago, it would be worth $64.18 as of February 05, 2025 at a share price of $0.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 03, 2025 9:30 PM GMT
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced tha
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
GlobeNewswire Inc.
Jan 21, 2025 10:05 PM GMT
27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels of carcinoembryonic antigen (CEA) and circulating tumo
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jan 10, 2025 10:00 PM GMT
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced tha